Breast Cancer-Basic and Clinical Research is a premier open access journal published by SAGE Publications Ltd, dedicated to advancing the understanding and treatment of breast cancer through a comprehensive approach that integrates basic and clinical research findings. Since its inception in 2008, this journal has aimed to serve as a vital platform for researchers, healthcare professionals, and students in the fields of oncology and cancer research, providing them with timely access to significant new research, clinical trials, and innovative methodologies. With its current rankings placing it in the Q3 quartile for Cancer Research and Oncology, it reflects a steady commitment to quality and relevance, ranking #167/404 in Medicine - Oncology and #133/230 in Biochemistry, Genetics and Molecular Biology - Cancer Research as of 2023. The journal is designed to foster dialogue and collaboration across disciplines, enabling advancements in therapeutic strategies and patient care. Researchers and professionals will find it an invaluable resource as it continues to push the frontiers of knowledge in breast cancer research.

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

The Journal of Gastrointestinal Oncology, published by AME Publishing Company, is a leading open-access journal that focuses on the complex interplay between gastroenterology and oncology. Established in 2012 and converging into a reputable academic platform through 2024, the journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and management of gastrointestinal cancers. With an ISSN of 2078-6891 and an E-ISSN of 2219-679X, this journal presents articles that are rigorously peer-reviewed, ensuring high-quality content that meets the demands of the scientific community. Despite its current categorization in the Q3 quartile for both Gastroenterology and Oncology as of 2023, it consistently strives to improve its impact and relevance, reflected in its Scopus rankings and percentile metrics. Publishing noteworthy research, reviews, and case studies, the Journal of Gastrointestinal Oncology is instrumental in addressing significant challenges in the field, making it a must-read for those dedicated to advancing knowledge and practice in gastrointestinal oncology.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.